Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Vaccine Adjuvants Market, by Type
1.4.2 Global Vaccine Adjuvants Market, by Administration
1.4.3 Global Vaccine Adjuvants Market, by Application
1.4.4 Global Vaccine Adjuvants Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2020, Feb – 2023, Oct) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. Global Vaccine Adjuvants Market, by Type
5.1 Global Particulate Market, by Region
5.2 Global Adjuvant Emulsion Market, by Region
5.3 Global Pathogen Market, by Region
5.4 Global Combination Market, by Region
5.5 Global Others Market, by Region
Chapter 6. Global Vaccine Adjuvants Market, by Administration
6.1 Global Intramuscular Market, by Region
6.2 Global Intranasal Market, by Region
6.3 Global Oral Market, by Region
6.4 Global Intradermal Market, by Region
6.5 Global Others Market, by Region
Chapter 7. Global Vaccine Adjuvants Market, by Application
7.1 Global Infectious Diseases Market, by Region
7.2 Global Cancer Market, by Region
7.3 Global Others Market, by Region
Chapter 8. Global Vaccine Adjuvants Market, by Region
8.1 North America Vaccine Adjuvants Market
8.1.1 North America Vaccine Adjuvants Market, by Type
8.1.1.1 North America Particulate Market, by Country
8.1.1.2 North America Adjuvant Emulsion Market, by Country
8.1.1.3 North America Pathogen Market, by Country
8.1.1.4 North America Combination Market, by Country
8.1.1.5 North America Others Market, by Country
8.1.2 North America Vaccine Adjuvants Market, by Administration
8.1.2.1 North America Intramuscular Market, by Country
8.1.2.2 North America Intranasal Market, by Country
8.1.2.3 North America Oral Market, by Country
8.1.2.4 North America Intradermal Market, by Country
8.1.2.5 North America Others Market, by Country
8.1.3 North America Vaccine Adjuvants Market, by Application
8.1.3.1 North America Infectious Diseases Market, by Country
8.1.3.2 North America Cancer Market, by Country
8.1.3.3 North America Others Market, by Country
8.1.4 North America Vaccine Adjuvants Market, by Country
8.1.4.1 US Vaccine Adjuvants Market
8.1.4.1.1 US Vaccine Adjuvants Market, by Type
8.1.4.1.2 US Vaccine Adjuvants Market, by Administration
8.1.4.1.3 US Vaccine Adjuvants Market, by Application
8.1.4.2 Canada Vaccine Adjuvants Market
8.1.4.2.1 Canada Vaccine Adjuvants Market, by Type
8.1.4.2.2 Canada Vaccine Adjuvants Market, by Administration
8.1.4.2.3 Canada Vaccine Adjuvants Market, by Application
8.1.4.3 Mexico Vaccine Adjuvants Market
8.1.4.3.1 Mexico Vaccine Adjuvants Market, by Type
8.1.4.3.2 Mexico Vaccine Adjuvants Market, by Administration
8.1.4.3.3 Mexico Vaccine Adjuvants Market, by Application
8.1.4.4 Rest of North America Vaccine Adjuvants Market
8.1.4.4.1 Rest of North America Vaccine Adjuvants Market, by Type
8.1.4.4.2 Rest of North America Vaccine Adjuvants Market, by Administration
8.1.4.4.3 Rest of North America Vaccine Adjuvants Market, by Application
8.2 Europe Vaccine Adjuvants Market
8.2.1 Europe Vaccine Adjuvants Market, by Type
8.2.1.1 Europe Particulate Market, by Country
8.2.1.2 Europe Adjuvant Emulsion Market, by Country
8.2.1.3 Europe Pathogen Market, by Country
8.2.1.4 Europe Combination Market, by Country
8.2.1.5 Europe Others Market, by Country
8.2.2 Europe Vaccine Adjuvants Market, by Administration
8.2.2.1 Europe Intramuscular Market, by Country
8.2.2.2 Europe Intranasal Market, by Country
8.2.2.3 Europe Oral Market, by Country
8.2.2.4 Europe Intradermal Market, by Country
8.2.2.5 Europe Others Market, by Country
8.2.3 Europe Vaccine Adjuvants Market, by Application
8.2.3.1 Europe Infectious Diseases Market, by Country
8.2.3.2 Europe Cancer Market, by Country
8.2.3.3 Europe Others Market, by Country
8.2.4 Europe Vaccine Adjuvants Market, by Country
8.2.4.1 Germany Vaccine Adjuvants Market
8.2.4.1.1 Germany Vaccine Adjuvants Market, by Type
8.2.4.1.2 Germany Vaccine Adjuvants Market, by Administration
8.2.4.1.3 Germany Vaccine Adjuvants Market, by Application
8.2.4.2 UK Vaccine Adjuvants Market
8.2.4.2.1 UK Vaccine Adjuvants Market, by Type
8.2.4.2.2 UK Vaccine Adjuvants Market, by Administration
8.2.4.2.3 UK Vaccine Adjuvants Market, by Application
8.2.4.3 France Vaccine Adjuvants Market
8.2.4.3.1 France Vaccine Adjuvants Market, by Type
8.2.4.3.2 France Vaccine Adjuvants Market, by Administration
8.2.4.3.3 France Vaccine Adjuvants Market, by Application
8.2.4.4 Russia Vaccine Adjuvants Market
8.2.4.4.1 Russia Vaccine Adjuvants Market, by Type
8.2.4.4.2 Russia Vaccine Adjuvants Market, by Administration
8.2.4.4.3 Russia Vaccine Adjuvants Market, by Application
8.2.4.5 Spain Vaccine Adjuvants Market
8.2.4.5.1 Spain Vaccine Adjuvants Market, by Type
8.2.4.5.2 Spain Vaccine Adjuvants Market, by Administration
8.2.4.5.3 Spain Vaccine Adjuvants Market, by Application
8.2.4.6 Italy Vaccine Adjuvants Market
8.2.4.6.1 Italy Vaccine Adjuvants Market, by Type
8.2.4.6.2 Italy Vaccine Adjuvants Market, by Administration
8.2.4.6.3 Italy Vaccine Adjuvants Market, by Application
8.2.4.7 Rest of Europe Vaccine Adjuvants Market
8.2.4.7.1 Rest of Europe Vaccine Adjuvants Market, by Type
8.2.4.7.2 Rest of Europe Vaccine Adjuvants Market, by Administration
8.2.4.7.3 Rest of Europe Vaccine Adjuvants Market, by Application
8.3 Asia Pacific Vaccine Adjuvants Market
8.3.1 Asia Pacific Vaccine Adjuvants Market, by Type
8.3.1.1 Asia Pacific Particulate Market, by Country
8.3.1.2 Asia Pacific Adjuvant Emulsion Market, by Country
8.3.1.3 Asia Pacific Pathogen Market, by Country
8.3.1.4 Asia Pacific Combination Market, by Country
8.3.1.5 Asia Pacific Others Market, by Country
8.3.2 Asia Pacific Vaccine Adjuvants Market, by Administration
8.3.2.1 Asia Pacific Intramuscular Market, by Country
8.3.2.2 Asia Pacific Intranasal Market, by Country
8.3.2.3 Asia Pacific Oral Market, by Country
8.3.2.4 Asia Pacific Intradermal Market, by Country
8.3.2.5 Asia Pacific Others Market, by Country
8.3.3 Asia Pacific Vaccine Adjuvants Market, by Application
8.3.3.1 Asia Pacific Infectious Diseases Market, by Country
8.3.3.2 Asia Pacific Cancer Market, by Country
8.3.3.3 Asia Pacific Others Market, by Country
8.3.4 Asia Pacific Vaccine Adjuvants Market, by Country
8.3.4.1 China Vaccine Adjuvants Market
8.3.4.1.1 China Vaccine Adjuvants Market, by Type
8.3.4.1.2 China Vaccine Adjuvants Market, by Administration
8.3.4.1.3 China Vaccine Adjuvants Market, by Application
8.3.4.2 Japan Vaccine Adjuvants Market
8.3.4.2.1 Japan Vaccine Adjuvants Market, by Type
8.3.4.2.2 Japan Vaccine Adjuvants Market, by Administration
8.3.4.2.3 Japan Vaccine Adjuvants Market, by Application
8.3.4.3 India Vaccine Adjuvants Market
8.3.4.3.1 India Vaccine Adjuvants Market, by Type
8.3.4.3.2 India Vaccine Adjuvants Market, by Administration
8.3.4.3.3 India Vaccine Adjuvants Market, by Application
8.3.4.4 South Korea Vaccine Adjuvants Market
8.3.4.4.1 South Korea Vaccine Adjuvants Market, by Type
8.3.4.4.2 South Korea Vaccine Adjuvants Market, by Administration
8.3.4.4.3 South Korea Vaccine Adjuvants Market, by Application
8.3.4.5 Singapore Vaccine Adjuvants Market
8.3.4.5.1 Singapore Vaccine Adjuvants Market, by Type
8.3.4.5.2 Singapore Vaccine Adjuvants Market, by Administration
8.3.4.5.3 Singapore Vaccine Adjuvants Market, by Application
8.3.4.6 Malaysia Vaccine Adjuvants Market
8.3.4.6.1 Malaysia Vaccine Adjuvants Market, by Type
8.3.4.6.2 Malaysia Vaccine Adjuvants Market, by Administration
8.3.4.6.3 Malaysia Vaccine Adjuvants Market, by Application
8.3.4.7 Rest of Asia Pacific Vaccine Adjuvants Market
8.3.4.7.1 Rest of Asia Pacific Vaccine Adjuvants Market, by Type
8.3.4.7.2 Rest of Asia Pacific Vaccine Adjuvants Market, by Administration
8.3.4.7.3 Rest of Asia Pacific Vaccine Adjuvants Market, by Application
8.4 LAMEA Vaccine Adjuvants Market
8.4.1 LAMEA Vaccine Adjuvants Market, by Type
8.4.1.1 LAMEA Particulate Market, by Country
8.4.1.2 LAMEA Adjuvant Emulsion Market, by Country
8.4.1.3 LAMEA Pathogen Market, by Country
8.4.1.4 LAMEA Combination Market, by Country
8.4.1.5 LAMEA Others Market, by Country
8.4.2 LAMEA Vaccine Adjuvants Market, by Administration
8.4.2.1 LAMEA Intramuscular Market, by Country
8.4.2.2 LAMEA Intranasal Market, by Country
8.4.2.3 LAMEA Oral Market, by Country
8.4.2.4 LAMEA Intradermal Market, by Country
8.4.2.5 LAMEA Others Market, by Country
8.4.3 LAMEA Vaccine Adjuvants Market, by Application
8.4.3.1 LAMEA Infectious Diseases Market, by Country
8.4.3.2 LAMEA Cancer Market, by Country
8.4.3.3 LAMEA Others Market, by Country
8.4.4 LAMEA Vaccine Adjuvants Market, by Country
8.4.4.1 Brazil Vaccine Adjuvants Market
8.4.4.1.1 Brazil Vaccine Adjuvants Market, by Type
8.4.4.1.2 Brazil Vaccine Adjuvants Market, by Administration
8.4.4.1.3 Brazil Vaccine Adjuvants Market, by Application
8.4.4.2 Argentina Vaccine Adjuvants Market
8.4.4.2.1 Argentina Vaccine Adjuvants Market, by Type
8.4.4.2.2 Argentina Vaccine Adjuvants Market, by Administration
8.4.4.2.3 Argentina Vaccine Adjuvants Market, by Application
8.4.4.3 UAE Vaccine Adjuvants Market
8.4.4.3.1 UAE Vaccine Adjuvants Market, by Type
8.4.4.3.2 UAE Vaccine Adjuvants Market, by Administration
8.4.4.3.3 UAE Vaccine Adjuvants Market, by Application
8.4.4.4 Saudi Arabia Vaccine Adjuvants Market
8.4.4.4.1 Saudi Arabia Vaccine Adjuvants Market, by Type
8.4.4.4.2 Saudi Arabia Vaccine Adjuvants Market, by Administration
8.4.4.4.3 Saudi Arabia Vaccine Adjuvants Market, by Application
8.4.4.5 South Africa Vaccine Adjuvants Market
8.4.4.5.1 South Africa Vaccine Adjuvants Market, by Type
8.4.4.5.2 South Africa Vaccine Adjuvants Market, by Administration
8.4.4.5.3 South Africa Vaccine Adjuvants Market, by Application
8.4.4.6 Nigeria Vaccine Adjuvants Market
8.4.4.6.1 Nigeria Vaccine Adjuvants Market, by Type
8.4.4.6.2 Nigeria Vaccine Adjuvants Market, by Administration
8.4.4.6.3 Nigeria Vaccine Adjuvants Market, by Application
8.4.4.7 Rest of LAMEA Vaccine Adjuvants Market
8.4.4.7.1 Rest of LAMEA Vaccine Adjuvants Market, by Type
8.4.4.7.2 Rest of LAMEA Vaccine Adjuvants Market, by Administration
8.4.4.7.3 Rest of LAMEA Vaccine Adjuvants Market, by Application
Chapter 9. Company Profiles
9.1 Novavax, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 SPI Pharma, Inc. (Associated British Foods PLC)
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.3 Agenus Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expenses
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.6 SWOT Analysis
9.4 InvivoGen SAS
9.4.1 Company Overview
9.4.2 SWOT Analysis
9.5 Seppic S.A. (L’Air Liquide S.A.)
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Product Launches and Product Expansions:
9.5.6 SWOT Analysis
9.6 Riboxx GmbH
9.6.1 Company Overview
9.7 GlaxoSmithKline PLC (GSK)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.7.5.3 Trials and Approvals:
9.7.6 SWOT Analysis
9.8 CSL Limited
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.6 SWOT Analysis
9.9 Croda International PLC
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Recent strategies and developments:
9.9.4.1 Partnerships, Collaborations, and Agreements:
9.9.4.2 Acquisition and Mergers:
9.10. Merck & Co., Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 Recent strategies and developments:
9.10.5.1 Acquisition and Mergers:
9.10.6 SWOT Analysis
Chapter 10. Winning Imperatives of Vaccine Adjuvants Market
Unique Offerings 
